The contraceptive vaginal ring (NuvaRing®) and hemostasis: A comparative study

Contraception

Volumn 69, Issue 6, 2004, Pages 461-467

  Magnusdottir E M ^a   Bjarnadottir R I ^a   Onundarson P T ^a   Gudmundsdottir B R ^a   Geirsson, R T ^a   Magnusdottir S D ^a   Dieben, Th O M ^b  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b Clinical Development Department   (Netherlands)

Author keywords

Coagulation; Fibrinolysis; Hemostasis; NuvaRing; Oral contraceptives

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPAREUNIA; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; LEUKORRHEA; LIBIDO DISORDER; MASTALGIA; MENSTRUAL IRREGULARITY; NAUSEA; NORMAL HUMAN; PROTEIN METABOLISM; SIDE EFFECT; SQUAMOUS EPITHELIUM; VAGINA RING; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BLOOD COAGULATION; CONTRACEPTIVE DEVICES, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FACTOR VII; FEMALE; HEMOSTASIS; HUMANS; LEVONORGESTREL;

EID: 2442430703     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.12.010     Document Type: Article

References (13)

1. Timmer C.J., Mulders T.M. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 39:2000;233-242
2. Mulders T.M., Dieben T.O. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril. 75:2001;865-870
3. Dieben T.O., Roumen F.J., Apter D. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 100:2002;585-593
4. Novak A., de la Loge C., Abetz L., van der Meulen E.A. The combined contraceptive vaginal ring, NuvaRing an international study of user acceptability. Contraception. 67:2003;187-194
5. Bjarnadóttir R.I., Tuppurainen M., Killick S.R. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol. 186:2002;389-395
6. Drife J. Oral contraception and the risk of thromboembolism. What does it mean to clinicians and their patients? Drug Saf. 25:2002;893-902
7. The Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables conclusions from a large randomized multicenter study. Contraception. 67:2003;173-185
8. Winkler U.H. Effects on hemostatic variables of desogestrel- andgestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives a review. Am J Obstet Gynecol. 179:1998;S51-S61
9. Middeldorp S., Meijers J.C., van den Ende A.E., et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives a cross-over study. Thromb Haemost. 84:2000;4-8
10. Cheung M.C., Walden C.E., Knopp R.H. Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-1-containing high-density lipoprotein particles. Metabolism. 48:1999;658-664
11. Singh M., Thomas D., Singh R., Saxena B.B., Ledger W.J. A triphasic oral contraceptive pill, CTR-05 clinical efficacy and safety. Eur J Contracept Reprod Health Care. 1:1996;285-292
12. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briët E., Vandenbroucke J.P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thromb Haemost. 71:1994;719-722
13. Janssen M.C., Verbruggen B.W., ter Hark P.J., Novakova I.P. Factor VIIA determination compared to D-dimer in diagnosis of deep venous thrombosis. Thromb Res. 86:1997;423-426